Oncternal Therapeutics, Inc.
ONCT · NASDAQ
9/30/2024 | 6/30/2024 | 3/31/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Market Cap | $0 | $0 | $0 | $0 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | -$0 | $0 | $0 | $0 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | -100% | 40.8% | 91.6% | – |
| Gross Profit | $0 | -$0 | -$0 | -$0 |
| % Margin | – | -636.7% | -964.9% | -2,145.8% |
| EBITDA | -$0 | $0 | $0 | -$0 |
| % Margin | – | 0% | 0% | -3,095.3% |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | – | -1,068.5% | -1,474.2% | -3,085.5% |
| EPS Diluted | -2.86 | -2.89 | -2.83 | -3.11 |
| % Growth | 1% | -2.1% | 9% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | $0 | $0 | $0 | $0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |